Novartis AG (NOVN) Operating Income 2021–2025

Name: Novartis AG (NOVN) operating income history 2021-2025
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-16

Novartis AG annual operating income for fiscal 2025 was $17.6 billion, an increase of 21.3% from $14.5 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

NOVN Annual Operating Income

Operating Income (annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Income (EBIT)	$17.6B	$14.5B	$9.8B	$7.9B	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NOVN Quarterly Operating Income

Operating Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Operating Income (EBIT)	$4.8B	$4.2B	$3.6B	$4.5B	$4.9B	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Operating Income at Comparable Companies

4568 Operating Income — Daiichi Sankyo Company, Limited
4503 Operating Income — Astellas Pharma Inc.
4528 Operating Income — Ono Pharmaceutical Co., Ltd.
4536 Operating Income — Santen Pharmaceutical Co., Ltd.

More NOVN metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow

All NOVN financial statements → Interactive NOVN charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.